Insight, China's Pharmaceutical Industry

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China’s National Medical Products Administration (NMPA)...

Company

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Fineline Cube Apr 29, 2026

Novartis AG (NYSE: NVS) reported Q1 2026 financial results showing USD 13.1 billion in net...

Company

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Fineline Cube Apr 29, 2026

Astellas Pharma Inc. (TYO: 4503) reported FY2025 financial results showing JPY 2,139.2 billion (USD 13.9...

Company

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Fineline Cube Apr 29, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results...

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026

Fosun Pharma (SHA: 600196; HKG: 2196) announced it has signed a Memorandum of Cooperation with...

Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Fineline Cube Apr 29, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has...

Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced a strategic partnership with Sun...

Company Medical Device

Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform

Fineline Cube Apr 29, 2026

Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and...

Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026

Vivacta Biotechnology, a Shanghai-based in vivo chimeric antigen receptor (CAR)-T therapy developer, announced the successful...

Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026

Insilico Medicine (HKG: 3696), a generative artificial intelligence (AI)-driven biotechnology company, announced it has received...

Company

Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness

Fineline Cube Apr 29, 2026

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported Q1 2026 financial results showing RMB...

Company Drug

Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required

Fineline Cube Apr 29, 2026

Immunotech Biopharm Ltd. (HKG: 6978), a chimeric antigen receptor T-cell (CAR-T) specialist based in China,...

Company Drug

GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma

Fineline Cube Apr 29, 2026

GluBio Pharmaceutical Co., Ltd., a molecular glue targeted protein degradation (TPD) specialist based in Zhejiang,...

Company Drug

Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta

Fineline Cube Apr 29, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received marketing authorization from the European...

Company Drug

AbbVie Submits FDA Application for RINVOQ in Severe Alopecia Areata – Expanding JAK Inhibitor Franchise

Fineline Cube Apr 29, 2026

AbbVie Inc. (NYSE: ABBV) announced the submission of a supplemental New Drug Application (sNDA) to...

Company Medical Device

Medtronic Secures CE Mark for Stealth AXiS Surgical System – Next-Generation Integrated Robotics Platform

Fineline Cube Apr 29, 2026

Medtronic plc (NYSE: MDT) announced it has received CE Mark approval for the Stealth AXiS...

Company Drug

Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements

Fineline Cube Apr 29, 2026

Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals,...

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026

Santo Therapeutics, a Hangzhou-based in vivo gene therapy developer, announced it has received both Orphan...

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that its supplemental Biologics License Application (sBLA) for...

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Fineline Cube Apr 28, 2026

AbbVie (NYSE: ABBV) announced it has submitted a marketing approval filing to the U.S. Food...

Insight, China's Pharmaceutical Industry

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness

Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required

GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma

Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta

AbbVie Submits FDA Application for RINVOQ in Severe Alopecia Areata – Expanding JAK Inhibitor Franchise

Medtronic Secures CE Mark for Stealth AXiS Surgical System – Next-Generation Integrated Robotics Platform

Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

You Missed

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs